Upregulation of MYBL1 induces the mRNA expression of ANGPT2 and significantly promotes HCC angiogenesis, enhanced sorafenib resistance both in vitro and in vivo. This evidence concerns the gene ANGPT2 and hepatocellular carcinoma.